Liaoning Chengda Biotechnology Co Ltd Class A 688739
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 27.76
- Price/Sales
- 5.75
- Dividend Yield (Trailing)
- 3.28%
- Dividend Yield (Forward)
- 3.28%
- Total Yield
- 3.28%
Company Profile
Liaoning Chengda Biotechnology Co Ltd is engaged in the research and development, production and sales of human vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,732
- Website
- http://www.cdbio.cn
Comparables
Valuation
|
Metric
|
688739
|
300122
|
301207
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.76 | 9.77 | 14.58 |
Price/Book Value | 1.07 | 1.84 | 1.72 |
Price/Sales | 5.75 | 1.24 | 4.43 |
Price/Cash Flow | 16.28 | 8.06 | 10.76 |
Price/Earnings
688739
300122
301207
Financial Strength
|
Metric
|
688739
|
300122
|
301207
|
|---|---|---|---|
Quick Ratio | 17.26 | 1.37 | 2.85 |
Current Ratio | 18.49 | 2.07 | 3.42 |
Interest Coverage | 288.58 | 76.85 | 149.96 |
Quick Ratio
688739
300122
301207
Profitability
|
Metric
|
688739
|
300122
|
301207
|
|---|---|---|---|
Return on Assets (Normalized) | 3.14% | 11.64% | 9.24% |
Return on Equity (Normalized) | 3.29% | 19.62% | 11.52% |
Return on Invested Capital (Normalized) | 2.81% | 17.67% | 10.82% |
Return on Assets
688739
300122
301207
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dcfmwlrvx | Ksqb | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cpyshdxsq | Kqktyv | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tggkkmjq | Yvxpksz | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qvtplqdhg | Wqcjvq | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Sxvbylrx | Xdbzr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Wptsncyty | Slws | $28.0 Bil | |||
| Moderna Inc
MRNA
| Kfbwtwfmd | Fnnw | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Pfdlgxgyn | Mxhzf | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kwpgdjgwy | Tpzzsgy | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Nmzsxpvwlm | Hfglb | $12.6 Bil |
United States